<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05005039</url>
  </required_header>
  <id_info>
    <org_study_id>2021_0045</org_study_id>
    <secondary_id>2021-A01440-41</secondary_id>
    <nct_id>NCT05005039</nct_id>
  </id_info>
  <brief_title>Bone Marrow Fat and Bariatric Surgery-Mediated Bone Loss</brief_title>
  <acronym>ADIMOS-OB</acronym>
  <official_title>Bone Marrow Fat and Bariatric Surgery-Mediated Bone Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Results are inconsistent and further studies are needed to better understand the impact of&#xD;
      bariatric surgery on the bone-BMA relationship depending on the type of bariatric surgery:&#xD;
      RYGB vs. SG. Future studies are also needed to define the molecular mediators of bone loss&#xD;
      and BMA changes. Several molecular mediators have been considered including gut hormones,&#xD;
      adipokines, gonadal hormones and more recently G-CSF. However, the evidence to support any of&#xD;
      these alone or in combination as primary mechanisms of bone loss is scant.&#xD;
&#xD;
      The study will be to explore potential changes in BMA after bariatric surgery and search for&#xD;
      possible associated factors. Specifically, we want to investigate if such changes in BMFF&#xD;
      differed in participants among different surgical types (RYGB vs. SG) and diabetic status.&#xD;
      Secondly, we want to explore factors associated with BMFF changes including metabolic&#xD;
      homeostasis (glycemic control and blood lipid levels), adipokines (leptin and adiponectin),&#xD;
      calciotropic hormones (Ca++, PTH…), body composition parameters and bone markers (cross-laps,&#xD;
      P1NP and sclerostin). We hypothesize that the BMFF would particularly decrease after RYGB&#xD;
      compared to SG and that participants with T2D would have a larger decrease in BMFF than&#xD;
      participants without T2D.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Variation in bone marrow fat fraction (BMFF) in %</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Bariatric Surgery in Postmenopausal Women</condition>
  <arm_group>
    <arm_group_label>Obese postmenopausal women who will undergo RYGB</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese postmenopausal women who will undergo SG</arm_group_label>
  </arm_group>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Sample population will be 40 postmenopausal women suffering from obesity.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Postmenopausal women (defined as last menses &gt;12 months)&#xD;
&#xD;
          -  Obesity with a BMI ≥ 35 kg/m²,&#xD;
&#xD;
          -  Patients with an indication for bariatric surgery with two surgical techniques, RYGB&#xD;
             and SG, but who have never had a bariatric surgery procedure previously,&#xD;
&#xD;
          -  Enrollment will be stratified for each surgical techniques, RYGB and SG, by&#xD;
             preoperative diabetes status, defined by having HbA1c &gt;6.5% or a prior physician's&#xD;
             diagnosis of diabetes plus use of an antidiabetic medication.&#xD;
&#xD;
          -  Patients who have signed the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  women who were pre- and perimenopausal and men in order to minimize sex hormone and&#xD;
             BMA changes unrelated to the surgical procedure.&#xD;
&#xD;
          -  women who used medications known to impact bone metabolism or BMA, including&#xD;
             bisphosphonates, teriparatide, denosumab, hormone replacement therapy (HRT) and oral&#xD;
             glucocorticoids (&gt;5mg prednisone equivalent daily for&gt;10 days in the last 3 months.&#xD;
&#xD;
          -  Other exclusion criteria included prior bariatric surgery, estimated glomerular&#xD;
             filtration rate &lt;30 mL/min,&#xD;
&#xD;
          -  any contraindication to magnetic resonance imagery (MRI).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien PACCOU, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien PACCOU, MD,PhD</last_name>
    <phone>0320445962</phone>
    <phone_ext>+33</phone_ext>
    <email>julien.paccou@chru-lille.fr</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

